可逆性气流受限预测SPIROMICS队列未来慢阻肺发生
基于SPIROMICS观察性队列,比较175例可变阻塞(VO,支气管舒张前FEV1/FVC<0.70、舒张后≥0.70)与603例无阻塞参照者。VO组未来发生慢阻肺的风险显著增高(HR 6.2,95%CI 4.6-8.3,P<0.001),且基线支气管舒张前后FEV1更低、随访中支气管舒张后FEV1及支气管舒张前后FVC下降更快;两组急性加重无显著差异。
要点
- 支气管舒张前FEV1/FVC<0.70而舒张后≥0.70者未来慢阻肺风险显著增高(HR 6.2)。
- VO组基线支气管舒张前后FEV1更低,随访中支气管舒张后FEV1及FVC下降更快。
- VO组与无阻塞参照者急性加重无显著差异。
核心结论
- 支气管舒张前存在而舒张后消失的气流受限者未来发生慢阻肺的风险显著增高。
- 研究结果支持考虑将支气管舒张前气流受限纳入慢阻肺诊断的肺功能标准。
研究设计与样本
- SPIROMICS观察性队列研究,比较175例可变阻塞者与603例无阻塞参照者。
- 模型均校正参与者特征、哮喘史和烟草暴露。
主要发现
- VO组未来发生慢阻肺的风险是无阻塞参照者的6.2倍(95%CI 4.6-8.3;P<0.001)。
- VO组基线支气管舒张前后FEV1显著低于参照组。
- VO组随访中支气管舒张后FEV1及支气管舒张前后FVC下降更显著。
- 两组急性加重率无显著差异。
关键数值与推荐
- 可变阻塞定义为支气管舒张前FEV1/FVC<0.70且支气管舒张后FEV1/FVC≥0.70。
- 慢阻肺定义采用支气管舒张后FEV1/FVC<0.70。
临床怎么用
- 解读肺功能时应关注支气管舒张前FEV1/FVC已<0.70但舒张后恢复至≥0.70者,其未来慢阻肺风险高。
- 对此类人群可加强随访肺功能监测,关注FEV1与FVC的下降趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Chronic obstructive pulmonary disease (COPD) is defined by fixed spirometric ratio, FEV1/FVC < 0.70 after inhaled bronchodilators. However, the implications of variable obstruction (VO), in which the prebronchodilator FEV1/FVC ratio is less than 0.70 but increases to 0.70 or more after inhaled bronchodilators, have not been determined. Objectives: We explored differences in physiology, exacerbations, and health status in participants with VO compared with reference participants without obstruction. Methods: Data from the SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study) cohort were obtained. Participants with VO were compared with reference participants without obstruction. Measurements and Main Results: We assessed differences in baseline radiographic emphysema and small airway disease at study entry, baseline, and change in lung function by spirometry, functional capacity by 6-minute walk, health status using standard questionnaires, exacerbation rates, and progression to COPD between the two groups. All models were adjusted for participant characteristics, asthma history, and tobacco exposure. We assessed 175 participants with VO and 603 reference participants without obstruction. Participants with VO had 6.2 times the hazard of future development of COPD controlling for other factors (95% confidence interval, 4.6-8.3; P < 0.001). Compared with reference participants, the VO group had significantly lower baseline pre- and post-bronchodilator (BD) FEV1, and greater decline over time in post-BD FEV1, and pre- and post-BD FVC. There were no significant differences in exacerbations between groups. Conclusions: Significant risk for future COPD development exists for those with pre- but not post-BD airflow obstruction. These findings support consideration of expanding spirometric criteria defining COPD to include pre-BD obstruction. Clinical trial registered with www.clinicaltrials.gov (NCT01969344).
引用
- Buhr RG, Barjaktarevic IZ, Quibrera PM, et al. Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. Am J Respir Crit Care Med. 2022. PMID: 35549640. doi:10.1164/rccm.202201-0094OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。